temozolomide

Additionally, it enhances the efficacy of temozolomide in glioma treatment through apoptotic pathways involving caspase-3 and caspase-9...Despite these promising findings, further research, including detailed mechanistic studies and clinical trials, is needed to fully understand calycosin's therapeutic mechanisms and validate its potential in human subjects. Developing advanced delivery systems and exploring synergistic therapeutic strategies could further enhance its clinical application and effectiveness.

P2, N=91, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024

P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | Trial completion date: Jan 2017 --> Mar 2026

P2, N=88, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

We identified key regulators, such as PAX8, and NKX2.5, potentially involved in temozolomide (TMZ) resistance. Notably, NKX2.5, more expressed in higher-grade gliomas, negatively impacts patient survival, and regulates genes involved in glucose metabolism.

P2, N=43, Active, not recruiting, Annick Desjardins, MD | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

Although most glioneuronal tumors typically have an indolent course relative to their diffuse glial counterparts, this case suggests that those arising in the setting of LS can have a worse prognosis. https://thejns.org/doi/10.3171/CASE24811.

In glioma cell cultures, k io precisely followed the dynamic changes of proliferation activity in growth cycles and response to temozolomide (TMZ) treatment...Upregulated aquaporin 4 (AQP4) expression were observed in most proliferating glioma cells and the knockout of AQP4 could largely slow down proliferation activity, suggesting AQP4 is the potential molecule connecting MRI-k io with proliferation activity. This study provides an ease-of-use, accurate, and non-invasive imaging method for the spatiotemporal monitoring of proliferation activity in glioma.

PITX1, TNFRSF11B, and IGFBP2 are key genes associated with the prognosis of GBM patients with TMZ resistance. The differential expression of these genes correlates with adverse outcomes in GBM patients, suggesting that they are valuable biomarkers for predicting patient prognosis and that they could serve as diagnostic biomarkers or treatment targets.

Although metastatic/multifocal paragangliomas are rare, their occasional relentless course may require complex multidisciplinary treatment in order to maximize neurological as well as oncological outcomes.

By survival analysis, low expression of SCN1A was associated with poor prognosis (p < 0.05; HR = 0.7), highlighting its potential prognostic role. The combination of temozolomide treatment with suppression of miR- 155 - 5p may provide a more effective and side-effect minimized brain cancer treatment strategy by reducing resistance.

The results of this study suggest that aberrant RAD51AP1 expression is a crucial mechanism by which EGFRvIII-mutant glioblastoma resists TMZ chemotherapy, laying the groundwork for future personalized medicine.

Current standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, are limited by drug resistance and the blood-brain barrier...eQTL-MR analysis identifies GBM-associated differentially expressed genes and constructs a protein-protein interaction (PPI) network.Integrating pQTL data from the deCODE database, pQTL-MR, and colocalization analyses validated the therapeutic potential of GPX7 and CXCL10.These findings provide new perspectives on GBM biology and suggest actionable targets for therapy. Despite limitations due to sample size and population-specific data, this study highlights GPX7 and CXCL10 as promising candidates for further investigation and lays the foundation for targeted GBM treatments.

Differentially expressed genes (DEGs) between FOSL1 overexpression groups were predominantly involved in ferroptosis, immune response, angiogenesis, vascular mimicry, autophagy, epithelial-mesenchymal transition (EMT), cancer cell stemness, temozolomide (TMZ) resistance, and NF-κB signaling...Notably, 8 upregulated (ITGA5, SDC1, PHLDB2, TNFRSF8, ADAM8, TLR7, STEAP3, and POU3F2) and 4 downregulated (IFIT1, FBXO16, ARL3, and BEX1) genes were identified, with implications for glioblastoma prognosis. This transcriptome investigation emphasizes the diverse functions of FOSL1 in different biological processes and signaling networks during the shift from proneural to mesenchymal state in glioblastoma.

P1/2, N=67, Recruiting, Northwell Health | Trial completion date: Jun 2026 --> Jun 2027

P2, N=94, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2025 --> Apr 2026

P1/2, N=42, Recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jan 2028 --> Jun 2028

P2, N=50, Recruiting, BPGbio | Trial primary completion date: Feb 2025 --> Sep 2025

P2, N=93, Active, not recruiting, Imvax | Trial primary completion date: Jan 2025 --> Sep 2025

P2, N=30, Recruiting, Geisinger Clinic | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=52, Active, not recruiting, Mayo Clinic | Trial primary completion date: Dec 2024 --> Jul 2024

P2, N=141, Recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

P2, N=23, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Mar 2026

After adjuvant therapy with radiotherapy and temozolomide, the patient presented with a growing mass in the right medial frontal lobe in March 2021...Mr. Daily-Lyles has nothing to disclose.

Preclinical studies propose that levetiracetam sensitizes malignant glioma cells to the methylating agent temozolomide. Dr. Lobbous has nothing to disclose.

The AUC of preoperative CEACAM1 for predicting prognosis was 0.716 (cutoff: 5857.5 pg/mL) and for TMZ resistance was 0.742 (cutoff: 6431 pg/mL). High preoperative CEACAM1 levels are associated with poor prognosis and TMZ resistance, serving as a potential biomarker to guide clinical evaluation and treatment.

Male Sprague-Dawley rats bearing intra-caudate nucleus (CN) C6 inoculation were randomly divided into nine groups as follows: sham, tumor, Temozolomide (TMZ) vehicle, TMZ, CBZ vehicle, CBZ at doses of 0.5, 1, 2 and 4 mg/kg. Our findings demonstrate that the administration of CBZ at a dosage of 1 mg/kg exerts advantageous impacts on both the survival rate and neurocognitive performance of rats within the GBM model. However, our results showed that CBZ may have toxic effects, especially in a dose of 4 mg/kg.

Chromatin immunoprecipitation (ChIP) and luciferase reporter assays confirmed that TGFBI is a direct STAT3 target and is required for the STAT3-induced promotion of cellular senescence, glycolysis, and drug resistance. The STAT3-TGFBI axis could be a potential target for senescence-targeted GBM therapy.

Furthermore, in glioma cell lines with unmethylated MGMT, the knockdown of ADAM12 enhanced sensitivity to TMZ by inhibiting the TNF-α/NF-κB pathway and reducing MGMT expression. In all, these results demonstrated that ADAM12 aids in shedding of membrane-bound TNF-a to drive TMZ resistance in glioma.

P4, N=30, Recruiting, Mayo Clinic | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025

P1/2, N=150, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting

P2, N=31, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=198 --> 31

P2, N=30, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Oct 2025

Tumor drug sensitivity analysis showed more sensitivity towards temozolomide, irinotecan, and cisplatin among high CNPY3 expression patients (P < 0.05).ConclusionIncreased CNPY3 expression impacts the immune microenvironment of glioma and enhances the migration and invasion of glioma. CNPY3 is recommended as a prognostic biomarker for glioma patients.

P=N/A, N=60, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

P2, N=27, Not yet recruiting, Cancer Hospital Affiliated of Shandong First Medical University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shando

Using patient-derived GBM cells, we identify lysosomal activity as a unique metabolic biomarker of tumorigenesis, controlling the efficacy of temozolomide (TMZ), a standard GBM therapy...The lysine restriction mimetic, homoarginine administration, significantly enhances the efficacy of anticancer therapies through lysosomal dysfunction. This study underscores the critical role of lysosomal function modulated by amino acid metabolism in GBM pathogenesis and treatment.

This study demonstrated the importance of classifying patients according to the 2021 WHO-defined criteria. The majority of IDH-wildtype anaplastic astrocytomas (grade 3) were reclassified as glioblastoma (grade 4). These analyses also shed light on the efficacy of TMZ in certain molecular subgroups, where the addition of TMZ to RT appeared to benefit patients regardless of MGMT methylation status.

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a crucial biomarker in glioblastoma (GBM) that influences response to temozolomide...By analyzing 180 GBM tissue samples, a Random Forest model was developed, achieving an AUC of 0.862. The findings suggest that THz spectroscopy offers a rapid, intraoperative alternative to traditional MGMT methylation detection methods, potentially enhancing surgical decision-making and personalized treatment strategies in GBM.

Doxorubicin Cisplatin, Irinotecan, Etoposide and Temozolomide were used to determine the anti-proliferative effect on CD133+VE cells. RNA sequencing revealed 126 differentially expressed lncRNAs (DELs) in CD133+VEcells among which lncRNA LOXL1-AS1 was highly upregulated and lncRNA PAX8-AS1 was significantly downregulated. These lncRNAs has been reported to be related to drug resistance, migration and epithelial- to- mesenchymal transmission (EMT), self-renewal and stemness properties contributing to poor prognosis and disease relapse.

This is a rare and heterogeneous group of challenging GISTs due to their diversity and absence of sensitivity to the tyrosine kinase inhibitor (TKI) imatinib...In SDH-deficient GISTs, the TKI olverembatinib has shown encouraging clinical activity but requires further clinical validation, while the HIF2a inhibitor bezultifan and temozolomide alone or in combination with the death receptor agonist 5 are under clinical investigation...Rare molecular alterations in quadruple WT GISTs require investigation for their oncogenic potential. Collaborative research and patient advocacy is critical for these extremely rare tumors.

Cell viability and apoptosis were assessed in GBM cell lines after water bath heating with radiation and/or temozolomide...Overall, adjuvant hyperthermia enhances CRT efficacy in GBM cells, with MHT improving survival outcomes in rodents. Sufficient intracranial heating and MIONP retention for repeated treatments was achieved, supporting further clinical translation.